PortfoliosLab logoPortfoliosLab logo
IPO Date
Jul 19, 2019

Highlights

EPS (TTM)
-$3.20
Total Revenue (TTM)
$40.58M
Gross Profit (TTM)
$22.42M
EBITDA (TTM)
-$63.56M
Year Range
$0.00 - $0.06
ROA (TTM)
-75.14%
ROE (TTM)
211.88%

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Celularity Inc

Performance

CELUW Performance Chart

Celularity Inc (CELUW) is down 60.0% since the beginning of the year. At $0 per share, CELUW is trading 89.2% below its 52-week high of $0. Investors who bought $1,000 worth of CELUW shares 5 years ago would now be looking at an investment worth $5.


Loading charts...

S&P 500 Index

Returns By Period

Celularity Inc (CELUW) has returned -60.00% so far this year and -87.00% over the past 12 months.


Celularity Inc

1D
32.65%
1M
-32.99%
YTD
-60.00%
6M
-69.62%
1Y
-87.00%
3Y*
-49.34%
5Y*
-64.90%
10Y*

Benchmark (S&P 500 Index)

1D
0.13%
1M
5.68%
YTD
11.16%
6M
11.10%
1Y
27.46%
3Y*
21.12%
5Y*
12.66%
10Y*
13.75%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CELUW Monthly Returns History

Based on dividend-adjusted daily data since Jul 19, 2019, CELUW's average daily return is +1.09%, while the average monthly return is +6.49%. At this rate, an investment would double in approximately 0.9 years.

Historically, 43% of months were positive and 57% were negative. The best month was Dec 2023 with a return of +545.2%, while the worst month was Dec 2022 at -73.6%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.

On a daily basis, CELUW closed higher 38% of trading days. The best single day was Mar 7, 2025 with a return of +264.7%, while the worst single day was May 29, 2025 at -50.1%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-42.77%-24.73%41.43%-9.09%-28.89%1.56%-60.00%
2025288.33%-41.34%-2.44%-0.25%50.38%-26.17%35.44%0.00%-41.50%-29.06%-1.20%-33.94%-9.72%
2024-20.75%18.29%9.60%-14.84%-42.86%-24.00%20.39%8.74%-49.25%77.23%11.51%-9.82%-55.00%
202336.36%-14.89%-21.67%3.50%1.29%-8.90%-15.01%-59.34%-23.23%25.32%-67.45%545.16%-39.39%
2022-43.02%65.33%69.11%14.60%-46.45%-31.31%-18.96%-8.12%-9.91%2.48%-37.03%-73.60%-92.33%
2021-56.94%25.00%-29.03%-1.82%20.37%4.62%7.35%-0.68%-20.69%-11.30%-1.96%-14.00%-70.14%

Benchmark Metrics

Celularity Inc has an annualized alpha of 1347.33%, beta of 0.33, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 23, 2019.

  • This stock participated in 232.49% of S&P 500 Index downside but only 5.74% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.33 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
1,347.33%
Beta
0.33
0.00
Upside Capture
5.74%
Downside Capture
232.49%

Return for Risk

Risk / Return Rank

CELUW ranks 25 for risk / return — below 25% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.


CELUW Risk / Return Rank: 2525
Overall Rank
CELUW Sharpe Ratio Rank: 2424
Sharpe Ratio Rank
CELUW Sortino Ratio Rank: 4242
Sortino Ratio Rank
CELUW Omega Ratio Rank: 4343
Omega Ratio Rank
CELUW Calmar Ratio Rank: 55
Calmar Ratio Rank
CELUW Martin Ratio Rank: 99
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Celularity Inc (CELUW) and compare them to S&P 500 Index.


CELUWBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.37

2.39

-2.76

Sortino ratio

Return per unit of downside risk

0.53

3.25

-2.73

Omega ratio

Gain probability vs. loss probability

1.07

1.43

-0.36

Calmar ratio

Return relative to maximum drawdown

-0.91

3.11

-4.03

Martin ratio

Return relative to average drawdown

-1.34

14.38

-15.72

Dividends

Dividend History


Celularity Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Celularity Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Celularity Inc was 99.84%, occurring on Jun 1, 2026. The portfolio has not yet recovered.

The current Celularity Inc drawdown is 99.78%.


Related event

Drawdown

Fall

Recovery

Underwater

2026 bear market2026
-99.84%Jun 2026
5y 4mo
5y 4moJan 2021 - now
COVID crash2020
-50.75%Apr 2020
1mo 10d2mo 14d
3mo 24dMar 2020 - Jun 2020
2020 bear market2020
-32.53%Nov 2020
1mo 25d1mo 7d
3mo 2dSep 2020 - Dec 2020
2020 bear market2020
-25.17%Dec 2020
3d10d
13dDec 2020 - Dec 2020
2019 bear market2019
-25.00%Jul 2019
6d2d
8dJul 2019 - Jul 2019

Drawdown Indicators


CELUWBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-99.84%

-56.78%

-43.06%

Max Drawdown (1Y)

Largest decline over 1 year

-91.83%

-9.10%

-82.73%

Max Drawdown (3Y)

Largest decline over 3 years

-95.94%

-18.90%

-77.04%

Max Drawdown (5Y)

Largest decline over 5 years

-99.75%

-25.43%

-74.32%

Max Drawdown (10Y)

Largest decline over 10 years

-33.92%

Current Drawdown

Current decline from peak

-99.78%

0.00%

-99.78%

Average Drawdown

Average peak-to-trough decline

-76.09%

-10.72%

-65.37%

Ulcer Index

Depth and duration of drawdowns from previous peaks

62.55%

1.97%

+60.58%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Celularity Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Celularity Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for CELUW relative to other companies in the Biotechnology industry. Currently, CELUW has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with CELUW

Add Celularity Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with CELUW